Sangamo Therapeutics (SGMOQ) Interest Expenses (2011 - 2025)

Sangamo Therapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $419.8 million for Q4 2025.

• On a quarterly basis, Interest Expenses rose 14.2% year-over-year to $419.8 million in Q4 2025; TTM through Dec 2025 was $419.8 million, a 14.2% increase from a year earlier, with the FY2025 full-year figure at $419.8 million, up 14.2% from the prior year.
• Interest Expenses grew to $419.8 million in Q4 2025 per SGMOQ's latest filing, from $367.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $419.8 million in Q4 2025 and bottomed at $51000.0 in Q3 2023.
• The 5-year median for Interest Expenses is $1.6 million (2021), against an average of $86.3 million.
• Across the five-year window, Interest Expenses slumped 97.16% in 2022 and surged 124080.21% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $1.7 million in 2021, then slumped by 83.35% to $283000.0 in 2022, then jumped by 124080.21% to $351.4 million in 2023, then grew by 4.59% to $367.6 million in 2024, then increased by 14.2% to $419.8 million in 2025.
• Per Business Quant, the three latest SGMOQ Interest Expenses figures stand at $419.8 million (Q4 2025), $367.6 million (Q4 2024), and $351.4 million (Q4 2023).